Lisa Campbell
Director of Regulatory Strategy

Lisa Campbell leads the regulatory and medical writing functions at Richmond Pharmacology. She is responsible for guiding regulatory strategy across all clinical studies, overseeing submissions, and supporting regulatory engagements with UK, EU, and international authorities.

She brings over two decades of experience in drug development, clinical medicine, and regulatory science. Lisa previously held senior consultancy positions at NDA Regulatory Science and SSI Strategy, where she advised on global clinical programmes for gene therapies and rare diseases.

During her nine years at the MHRA, Lisa was a Senior Medical Assessor in the Clinical Trials Unit. Her work included developing innovative licensing processes (ILAP), shaping patient and public involvement strategies, and leading assessments for first-in-human and adaptive platform trials.

Lisa trained in Obstetrics and Gynaecology and holds an MD (postgraduate research degree) in Diabetes in Pregnancy. She is widely published in Nature Medicine, BMJ Open, and JAMA, and is an expert in regulatory compliance, trial design, and policy development.

At Richmond Pharmacology, Lisa is focused on delivering innovative, inclusive, and compliant regulatory solutions that accelerate access to new therapies.

Back to experts

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event